Latest Research on Long Covid Treatments

Our collaborative research reveals that a #wearable electrical nerve stimulation device (Quell Fibromyalgia) may reduce fibromyalgia-like symptoms (e.g., pain and fatigue) in long-COVID patients. In just four weeks, the device delivered low-voltage electrical currents, resulting in 26% greater pain relief and improved walking performance compared to a placebo device. This innovative solution also holds promise for managing chronic symptoms in other conditions, offering hope for a non-invasive, accessible approach. Published in Nature Scientific Reports, the study highlights a breakthrough for millions affected by long-COVID. This study was supported by a grant from the National Science Foundation (NSF) IUCRC Program C2SHiP with mentorship of NeuroMetrix, Inc., our C2SHIP industrial members. #LongCOVID #DigitalHealth #ChronicPain #FatigueManagement #TENSDevice #HealthInnovation #PrecisionMedicine #COVIDRecovery #WearableTechnology Shai Gozani Janet Roveda David Armstrong Margaret Halstead Naomi Hachen Marjorie Skubic Kouhyar Tavakolian Chiara Daraio Nicole Zahradka Mohan Kumar UCLA Alejandro Zulbaran Rasha Bara Myeounggon Lee Miguel Bargas Ochoa Tina Phan Areli Flores-Camargo Syed Murtaza Kazmi Mohammad Amin Dehghan Rouzi Fidaa Shaib https://lnkd.in/gpgGYYPq

Researchers from Serbia investigated the potential benefits of creatine supplements for individuals with long COVID. 90-95% of participants adhered to the supplement regimen and the creatine group reported greater improvements in long COVID symptoms such as loss of smell and taste, breathing difficulties, and body aches. The researchers proposed that creatine might aid in energy production in the brain and muscles or protect nerve cells, given its anti-inflammatory and antioxidant properties. Despite the encouraging findings, the study's limited sample size means further research is needed. https://lnkd.in/gJSXtMCt

Targeting the Epipharynx to Disrupt the Residual Triggers of COVID-19 in Patients with Long COVID – Japanese researchers identify the epipharynx as a possible reservoir of SARS-CoV-2 in Long Covid patients. The researchers found residual SARS-CoV-2 RNA in this tissue, and also demonstrated the presence of SARS-CoV-2 active signaling pathways in epithelial and immune cells in the epipharynx known to be expressed. Of note, treatment with epipharyngeal abrasive therapy (EAT) significantly reduced or eliminated the viral RNA, and it also decreased the inflamed dysfunctional ciliated epithelium. The findings suggest that SARS-CoV-2 spike RNA and SARS-CoV-2-related inflammation may persist in the epipharynx for more than six months post infection. They also provide a therapeutic tool to reduce the chronic inflammation of the epipharynx in some Long Covid patients. https://lnkd.in/gtKpzUcu #longcovid #COVID19  #health #globalhealth #publichealth #medicine #biotechnology #pharmaceuticals #pandemic #infectiousdiseases #FDA #WHO #CDC #ECDC #immunology